Skip to main content

Table 1 Baseline demographic and ART related characteristics

From: A randomized comparison of health-related quality of life outcomes of dolutegravir versus efavirenz-based antiretroviral treatment initiated in the third trimester of pregnancy

Characteristics

Dolutegravir (n = 82)

Efavirenz (n = 89)

Total (n = 171)

Treatment site

 Uganda

48 (59%)

54 (61%)

102 (60%)

 South Africa

34 (41%)

35 (39%)

69 (40%)

Married

 Yes

14 (17%)

9 (10%)

23 (13%)

 No

68 (83%)

80 (90%)

148 (87%)

Currently employed

 Yes

35 (43%)

30 (33%)

65 (38%)

 No

47 (57%)

59 (66%)

106 (62%)

Phone financial transactions

 Yes

54 (66%)

57 (64%)

111 (65%)

 No

28 (34%)

32 (36%)

60 (35%)

Own bank account

 Yes

38 (46%)

41 (46%)

79 (46%)

 No

44 (54%)

48 (54%)

92 (54%)

Used internet

 Yes

41 (50%)

44 (49%)

85 (50%)

 No

41 (50%)

45 (51%)

86 (50%)

Education level

 Primary

17 (21%)

28 (32%)

45 (26%)

 Secondary

50 (61%)

43 (48%)

93 (54%)

 Higher/university

2 (2%)

3 (3%)

5 (3%)

 Tertiary/vocational

2 (2%)

3 (3%)

5 (3%)

 No education

11 (14%)

12 (14%)

23 (14%)

Listen to radio

 At least once a week

68 (83%)

73 (82%)

141 (82%)

 Less than once a week

8 (10%)

9 (10%)

17 (10%)

 Not at all

6 (7%)

7 (8%)

13 (8%)

Watch television

 At least once a week

64 (79%)

77 (86%)

141 (83%)

 Less than once a week

6 (7%)

5 (6%)

11 (7%)

 Not at all

11 (14%)

6 (7%)

17 (10%)

Age (years)

27.5 (5.1)

27.5 (5.0)

27.5 (5.0)

Treatment duration (weeks)

56.3 (28.4)

55.9 (30.1)

56.1 (29.2)

Log10 viral load (copies per mL)a

4.0 (1.1)

4.2 (0.9)

4.1 (1.1)

CD4 at enrollment (cell per µL)a

514.9 (283.7)

456.6 (225.2)

484.6 (270)

PHS score

69.9 (11.9)

70.7 (9.2)

70.3 (10.6)

MHS score

81.2 (16.8)

81.5 (15.6)

81.4 (16.1)

  1. Data are n (%) and mean (SD)
  2. aAt enrollment